Scilex Holding (SCLX) Other financing activities (2021 - 2025)
Scilex Holding (SCLX) posted quarterly Other financing activities of -$10.2 million for Q4 2025, down 1018.8% year-over-year from $1.1 million in Q4 2024, and down 200.0% quarter-over-quarter from $10.2 million in Q3 2025.
Scilex Holding (SCLX) Other financing activities (2021 - 2025) Analysis & Trends
Scilex Holding's Other financing activities history runs 5 years deep, the most recent figure standing at -$10.2 million for Q4 2025.
- In Q4 2025, Other financing activities fell 1018.8% year-over-year to -$10.2 million; the TTM figure through Sep 2025 stood at $9.3 million (up 5111.83% YoY), while the FY2022 annual figure was $96000.0, changed N/A from the prior year.
- Other financing activities for Q4 2025 stood at -$10.2 million, down from $10.2 million in the prior quarter.
- The five-year high for Other financing activities was $10.2 million in Q3 2025, with the low at -$10.2 million in Q4 2025.
- The 5-year median for Other financing activities is $216500.0 (2022), against an average of $8000.0.
- Peak annual rise in Other financing activities reached 1824.25% in 2025, while the deepest fall reached 1018.8% in 2025.
- Scilex Holding's Other financing activities stood at -$5.1 million in 2021, then surged by 101.87% to $96000.0 in 2022, then plunged by 1246.88% to -$1.1 million in 2023, then grew by 16.89% to -$915000.0 in 2024, then tumbled by 1018.8% to -$10.2 million in 2025.
- Business Quant data shows SCLX's Other financing activities at -$10.2 million in Q4 2025, $10.2 million in Q3 2025, and -$915000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -10.24 Mn |
| Dec 31, 2025 | -10.24 Mn |
| Sep 30, 2025 | 10.24 Mn |
| Sep 30, 2025 | 10.24 Mn |
| Dec 31, 2024 | -915,000.00 |
| Dec 31, 2024 | -915,000.00 |
| Sep 30, 2024 | 532,000.00 |
| Sep 30, 2024 | 532,000.00 |
| Jun 30, 2024 | 337,000.00 |
| Jun 30, 2024 | 337,000.00 |
| Mar 31, 2024 | 46,000.00 |
| Mar 31, 2024 | 46,000.00 |
| Dec 31, 2023 | -1.10 Mn |
| Dec 31, 2023 | -1.10 Mn |
| Sep 30, 2023 | 358,000.00 |
| Sep 30, 2023 | 358,000.00 |
| Jun 30, 2023 | 743,000.00 |
| Jun 30, 2023 | 743,000.00 |
| Mar 31, 2022 | 96,000.00 |
| Mar 31, 2022 | 96,000.00 |